Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body (metastatic).
- The amount of spread is 'low volume' – which means fewer than 4 bone spots and no spread to organs like the liver or lungs.
- You are currently being treated with a combination of hormone therapy (ADT), chemotherapy (docetaxel), and darolutamide (a tablet), or your doctor has decided to start this treatment.
- You started hormone therapy within the last 6 months, or are starting it now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This study tests a triple treatment (darolutamide, hormone therapy, and chemotherapy) for men whose prostate cancer has spread and still responds to hormone therapy. The goal is to see if this combination works better than standard care in controlling the cancer and improving outcomes.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.